Categories: News

West Island Makes First Delivery to SQDC

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Dorval, Quebec–(Newsfile Corp. – June 28, 2022) – West Island Brands Inc. (CSE: WIB) (FSE: 39N0) (OTC Pink: WIBFF) (“West Island” or the “Company”) is pleased to announce that further to our news release of January 17, 2022, West Island’s subsidiary, RoyalMax Biotechnology Canada Inc. D.B.A West Island Culture has forwarded its first shipments cannabis products to the Province of Quebec.

West Island has been approved for a general listing of four SKUs in by the Société Québécoise Du Cannabis (the “SQDC”):

  • OUESTTM: Our premium brand will be represented by ‘Grandpa’s Stash’ and ‘Jelly Cake’ flower offerings. Both products stand out for the high content of THC and terpenes. We are convinced that these products will be appreciated by cannabis connoisseurs who are looking for products without compromise.
  • CITOYENTM: Our “People’s Flower” brand will be represented by the “King Louis” and “Clementine Punch” flower offerings. Both of these products come with unique terpene profiles. We are also confident that these two products will validate our brand’s mission to bring high quality craft cannabis to all consumers.

West Island CEO, Boris Ziger states, “West Island is thrilled to finally be in its home province of Quebec. Since the success of CITIZEN™ and our premium brands OUEST™ of craft cannabis in other parts of Canada, we can’t wait to bring them home. We expect Quebec to be one of our biggest markets in Canada, which makes it a very important step in the development of the company.”

About West Island

West Island is a multi-faceted, innovative company in the Quebec cannabis space. Its subsidiary, RoyalMax Biotechnology Canada Inc. is a Dorval, Quebec based Health Canada Licence Holder with standard cultivation licence, standard processing, medical sales and sales licences. The Company continues to work with Yunify Natural Technologies, a Quebec based health and personal care research and innovation company to develop proprietary products for West Island including topicals and ionic mists. Through its acquisition of Trichome Treats, an award-winning chocolatier, the Company intends on introducing edibles into the West Island product mix.

For more information on West Island Brands please visit the website at: westislandbrands.com.

On behalf of the Board of Directors
WEST ISLAND BRANDS INC.

Boris Ziger

Boris Ziger, CEO & Chairman

The Company’s public filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact:
Boris Ziger, CEO at:
Telephone: 416-304-9935
E-mail:
info@westislandbrands.com
Website:
www.westislandbrands.com

Boris Ziger, PDG de :
Téléphone : 416-304-9935
Courriel : info@westislandbrands.com
Site Web : www.westislandbrands.com

Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129208

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

1 day ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

1 day ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

1 day ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

1 day ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

1 day ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

1 day ago